Leukemia, 2004, 18, 887-888.
Gambacorti-Passerini C.
TO THE EDITOR
The report from Chand et al. offers clinical confirmation to our initial
findings, although the data are, as for any unplanned clinical observation
on a single patient, far from definitive and require further verification.
In certain conditions of particular demand, such as the repopulation after
cytotoxic treatment as described in our paper (1) the stimulation with
growth factors (2) or the clinical situation presented by Chand, it is
likely that the known inhibitory effect of imatinib on c-Kit, can cause
clinically evident alterations.
References
(1) Ruchatz H, Puttini M, Cleris L, Pilotti S, Gambacorti-Passerini C,
Formelli F. Effect of imatinib on haematopoietic recovery following
idarubicin exposure. Leukemia 2003; 17: 298-304.
PubMed
(2) Hui CH, Goh KY, White D, Branford S, Grigg A, Seymour JF et al.
Successful peripheral blood stem cell mobilisation with filgrastim in
patients with chronic myeloid leukaemia achieving complete cytogenetic
response with imatinib, without increasing disease burden as measured by
quantitative real-time PCR. Leukemia 2003; 17: 821-828.
PubMed
|
